CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is supported by Casgevy’s accelerating commercial ramp, with 3Q:26 sales of $99.2M topping Street estimates of $76.5M and infusions through 3Q:26 more than doubling FY:25 levels, reinforcing confidence in a durable launch trajectory. Beyond the approved franchise, the company’s pipeline adds optionality: CTX310 showed one-year durability with about a 78.6% ANGPTL3 reduction and meaningful LDL-C and triglyceride declines, while zugo-cel posted early activity with a 67% rCRISS 25 response at 1 month in systemic sclerosis. With an estimated YE:26 cash balance near $2.2B and a valuation framework that assigns meaningful value to Casgevy and multiple clinical assets, the fundamentals support a constructive long-term outlook.

CRISPR Therapeutics is viewed negatively because its core commercial driver, Casgevy, may fail to accelerate sales while several earlier-stage programs could be discontinued, leaving the company vulnerable to pipeline attrition and weak monetization. The business faces substantial clinical, durability, manufacturing, competitive, and legal risks, including possible failure of exa-cel, CTX112, CTX310, CTX340, CTX460, and CTX611, plus uncertainty around CRISPR/Cas9 intellectual property and reliance on partners such as Vertex and Bayer. Financially, the company may need additional equity financing to complete development, which would dilute shareholders, and the bear case implies 30% downside versus the base case.